Miravirsen is a drug that binds to and blocks the function of a cellular microRNA called miR-122 that is required for the replication of hepatitis C virus (HCV). Treatment of chimpanzees chronically infected with HCV with this drug leads to suppression of viral replication. The results of a phase 2b human clinical trial in HCV …
Treating hepatitis C by blocking a cellular microRNA Read More »
Episode #235 of the science show This Week in Virology was recorded before an audience at the 2nd Li Ka Shing Institute of Virology Symposium at the University of Alberta, where they spoke with Dave, Stan, and Lorne about their work on poxvirus vaccines and recombination, an enveloped picornavirus, antivirals against hepatitis B and C viruses, …
The spring semester has just ended at Columbia University, which means that my annual virology course has also concluded. The course met twice weekly, during which time we discussed the basic principles of virology, including how virions are built, how they replicate, and how they cause disease. For the last two lectures of the course …
Episode #234 of the science show This Week in Virology was recorded before an audience at the 2013 General Meeting of the American Society for Microbiology in Denver, Colorado. Vincent and Kathy spoke with Nels Elde and Tom Shenk about their work on the evolution of virus-host conflict and how viruses influence the cell metabolome. You can …
There have been 131 confirmed human infections with avian influenza H7N9 virus in China, but so far there is little evidence for human to human transmission. Three out of four patients report exposure to animals, ‘mostly chickens‘, suggesting that most of the infections are zoonoses. Whether or not the virus will evolve to transmit among …
Inefficient influenza H7N9 virus aerosol transmission among ferrets Read More »
At the 2013 ASM meeting in Denver, Colorado, Stanley Maloy discussed human infections with avian influenza H7N9 virus with Ronald Atlas, Ph.D., University of Louisville, KY; Robert Webster; St. Jude’s Research Hospital, Memphis, TN; Albert Osterhaus; Erasmus Medical Center, Rotterdam, The Netherlands; and Carole Heilman, NIAID, NIH, Bethesda, MD.
